| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0....
— So far this year alone, 25 TULSA-related scientific research presentations have been delivered at major medical meetings arou...
Alliance Global Partners analyst Ben Haynor maintains Profound Medical (NASDAQ:PROF) with a Buy and lowers the price target ...
Stifel analyst Rick Wise maintains Profound Medical (NASDAQ:PROF) with a Hold and lowers the price target from $11 to $9.
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.420) per share which missed the analyst consensus estimate of $...
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on rev...
The closing of the Private Placement is expected to occur on or about January 17, 2024, subject to customary closing conditions.
